A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...

The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...

In a study published in Cell Stem Cell, scientists tested retinal pigment epithelial stem cells in a phase 1/2a clinical trial. The cells were obtained from adult postmortem eye tissue. These ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...

ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...

The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study ...

In this video, David A. Eichenbaum, MD, FASRS, discusses late-stage wet age-related macular degeneration assets presented at the American Academy of Ophthalmology meeting.Eichenbaum noted that ...

Science Corporation has developed a revolutionary retinal implant called PRIMA. This eye chip restores functional vision for individuals with irreversible sight loss. The technology uses ...

According to Liu, his preferred option is faricimab, a fairly new agent that was FDA-approved for wet AMD in 2022. The drug ...

A new technology may allow patients to recover vision for conditions that were previously thought irreversible ...